How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | NBIXNEUROCRINE BIOSCIENCES INC | UTHRUNITED THERAPEUTICS Corp | INCYINCYTE CORP | INSMINSMED Inc | Median of the restexcluding NBIX |
|---|---|---|---|---|---|
| Type | Company | Company | Company | Company | |
| Price | $143.29▲ 1.98 (1.40%) | $563.49▲ 9.61 (1.74%) | $116.93▲ 3.49 (3.08%) | $94.04▼ 1.63 (1.70%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 10.0/10 | 8.7/10 | 10.0/10 | 5.0/10 | 8.7/10 |
| Market value | $14.34B | $24.59B | $23.21B | $20.15B | |
| Revenue | $2.86B | $3.18B | $5.14B | $606.4M | |
| Profit | $478.6M | $1.33B | $1.29B | -$1.28B | |
| Revenue growthChange in sales versus the prior year. | 21.4% | 10.6% | 21.2% | 66.7% | 21.2% |
| Gross marginShare of sales left after the direct cost of producing them. | 98.2% | 87.9% | 92.8% | 79.7% | 87.9% |
| Operating marginShare of sales left after running the business, before interest and tax. | 21.6% | 46.9% | 29.5% | -205.6% | 29.5% |
| Profit marginProfit kept from each dollar of sales. | 16.7% | 41.9% | 25.0% | -210.5% | 25.0% |
| Free cash flow marginCash left after capital spending, as a share of sales. | 26.2% | 32.7% | — | -159.6% | -63.4% |
| Return on equityProfit against the owners' stake in the company. | 14.7% | 18.8% | 24.9% | -172.8% | 18.8% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | 16.5% | 21.0% | 56.6% | -128.0% | 21.0% |
| P/E ratioPrice paid per dollar of annual profit. | 29.97x | 18.43x | 18.04x | — | 18.23x |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | — | — | — | — | — |
| Price to book | 4.41x | 3.47x | 4.49x | 27.27x | 4.49x |
| Debt to equityTotal liabilities compared with owners' stake. | 0.42x | 0.11x | 0.35x | 2.06x | 0.35x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 5/8 | 7/8 | 6/8 | 4/9 | 6.0 |
| Bankruptcy riskAltman Z-Score zone. | safe | safe | safe | safe |
How NBIX compares with the others
- NBIX's operating margin of 21.6% is lower than the median of the other companies selected (29.5%).
- Its revenue growth of 21.4% is in line with the median of the other companies selected (21.2%).
- It trades at a higher P/E than the median of the other companies selected: 30.0x against 18.2x.
- Its liabilities are higher relative to equity than the median of the other companies selected: 0.4x against 0.3x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.